Alnylam's HELIOS-A Trial Meets Secondary Endpoints At 18 Mon

WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals Inc.'s (ALNY) phase III trial of investigational RNAi therapeutic Vutrisiran in patients with hATTR amyloidosis with polyneuropathy has met all secondary

Related Keywords

Washington , United States , Ionis Tegsedi , Alnylam Onpattro , Alnylam Pharmaceuticals Inc , Neuropathy Impairment Score , Norfolk Quality , Life Questionnaire Diabetic Neuropathy , Alnylam , Helios , Trial , Meets , Secondary , Endpoints , Months , Vutrisiran , Races ,